Rational Design, Synthesis, and Biological Evaluation of Progesterone-Modified MRI Contrast Agents

Chemistry and Biology

Volumn 14, Issue 7, 2007, Pages 824-834

  Lee, Jiyoun ^a   Burdette, Joanna E ^b   MacRenaris, Keith W ^a   Mustafi, Devkumar ^c   Woodruff, Teresa K ^b   Meade, Thomas J ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

CHEMBIOL

Indexed keywords

CONTRAST MEDIUM; GADOLINIUM; PROGESTERONE; PROGESTERONE RECEPTOR;

ARTICLE; BREAST TUMOR; CHEMISTRY; DRUG DESIGN; DRUG SCREENING; FLUORESCENCE MICROSCOPY; HUMAN; METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

BREAST NEOPLASMS; CONTRAST MEDIA; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MICROSCOPY, FLUORESCENCE; PROGESTERONE; RECEPTORS, PROGESTERONE;

EID: 34447625764     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2007.06.006     Document Type: Article

References (29)

1. Merbach A.E., and Toth E. The Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging (2001), John Wiley and Sons, New York
2. Webb S. The Physics of Medical Imaging (1993), Institute of Physics Publishing, Bristol, UK and Philadelphia
3. Allen M.J., and Meade T.J. Metal Ions in Biological Systems Volume 42 (2004), Fontis Media, New York
4. Meade T.J., Taylor A.K., and Bull S.R. New magnetic resonance contrast agents as biochemical reporters. Curr. Opin. Neurobiol. 13 (2003) 597-602
5. Jacobs R.E., and Cherry S.R. Complementary emerging techniques: high-resolution PET and MRI. Curr. Opin. Neurobiol. 11 (2001) 621-629
6. Caravan P., Ellison J.J., McMurry T.J., and Lauffer R.B. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev. 99 (1999) 2293-2352
7. Louie A.Y., Huber M.M., Ahrens E.T., Rothbacher U., Moats R., Jacobs R.E., Fraser S.E., and Meade T.J. In vivo visualization of gene expression using magnetic resonance imaging. Nat. Biotechnol. 18 (2000) 321-325
8. Li W.H., Parigi G., Fragai M., Luchinat C., and Meade T.J. Mechanistic studies of a calcium-dependent MRI contrast agent. Inorg. Chem. 41 (2002) 4018-4024
9. Duimstra J.A., Femia F.J., and Meade T.J. A Gd(III) chelate for detection of β-glucuronidase: a self-immolative approach. J. Am. Chem. Soc. 127 (2005) 12847-12855
10. Allen M.J., MacRenaris K.W., Venkatasubramanian P.N., and Meade T.J. Cellular delivery of MRI contrast agents. Chem. Biol. 11 (2004) 301-307
11. Artemov D., Mori N., Ravi R., and Bhujwalla Z.M. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 63 (2003) 2723-2727
12. Ismail P.M., Amato P., Soyal S.M., DeMayo F.J., Conneely O.M., O'Malley B.W., and Lydon J.P. Progesterone involvement in breast development and tumorigenesis-as revealed by progesterone receptor "knockout" and "knockin" mouse models. Steroids 68 (2003) 779-787
13. Lanari C., and Molinolo A.A. Progesterone receptors-animal models and cell signalling in breast cancer. Diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer. Breast Cancer Res. 4 (2002) 240-243
14. Jacobsen B.M., Richer J.K., Sartorius C.A., and Horwitz K.B. Expression profiling of human breast cancers and gene regulation by progesterone receptors. J. Mammary Gland Biol. Neoplasia 8 (2003) 257-268
15. Bardou V.J., Arpino G., Elledge R.M., Osborne C.K., and Clark G.M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J. Clin. Oncol. 21 (2003) 1973-1979
16. Hopp T.A., Weiss H.L., Hilsenbeck S.G., Cui Y., Allred D.C., Horwitz K.B., and Fuqua S.A. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin. Cancer Res. 10 (2004) 2751-2760
17. Arpino G., Weiss H., Lee A.V., Schiff R., De Placido S., Osborne C.K., and Elledge R.M. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J. Natl. Cancer Inst. 97 (2005) 1254-1261
18. Cui X., Schiff R., Arpino G., Osborne C.K., and Lee A.V. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J. Clin. Oncol. 23 (2005) 7721-7735
19. Muss H.B. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res. Treat. 21 (1992) 15-26
20. Allen M.J., and Meade T.J. Synthesis and visualization of a membrane-permeable MRI contrast agent. J. Biol. Inorg. Chem. 8 (2003) 746-750
21. Rao G.S. Mode of entry of steroid and thyroid hormones into cells. Mol. Cell. Endocrinol. 21 (1981) 97-108
22. Golub M.S., Kaufman F.L., Campbell M.A., Li L.H., and Donald J.M. "Natural" progesterone: information on fetal effects. Birth Defects Res. B Dev. Reprod. Toxicol. 77 (2006) 455-470
23. Lee J., Zylka M.J., Anderson D.J., Burdette J.E., Woodruff T.K., and Meade T.J. A steroid-conjugated contrast agent for magnetic resonance imaging of cell signaling. J. Am. Chem. Soc. 127 (2005) 13164-13166
24. Andre F., and Pusztai L. Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. Nat. Clin. Pract. Oncol. 3 (2006) 621-632
25. Madauss K.P., Deng S.J., Austin R.J., Lambert M.H., McLay I., Pritchard J., Short S.A., Stewart E.L., Uings I.J., and Williams S.P. Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J. Med. Chem. 47 (2004) 3381-3387
26. So S.S., van Helden S.P., van Geerestein V.J., and Karplus M. Quantitative structure-activity relationship studies of progesterone receptor binding steroids. J. Chem. Inf. Comput. Sci. 40 (2000) 762-772
27. Bursi R., and Groen M.B. Application of (quantitative) structure-activity relationships to progestagens: from serendipity to structure-based design. Eur. J. Med. Chem. 35 (2000) 787-796
28. Williams S.P., and Sigler P.B. Atomic structure of progesterone complexed with its receptor. Nature 393 (1998) 392-396
29. Alvarez Nunez F.A., and Yalkowsky S.H. Correlation between log P and ClogP for some steroids. J. Pharm. Sci. 86 (1997) 1187-1189